Trial reportJournal of cataract and refractive surgery2026
Efficacy of intracameral moxifloxacin in prevention of postcataract surgery endophthalmitis: randomized control trial.
Trial report in Journal of cataract and refractive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comment on: Efficacy of intracameral moxifloxacin in prevention of postcataract surgery endophthalmitis: randomized control trial.Journal of cataract and refractive surgery · 2026Article
- Reply : Efficacy of intracameral moxifloxacin in prevention of postcataract surgery endophthalmitis: randomized control trial.Journal of cataract and refractive surgery · 2026Article
- Reply : Efficacy of intracameral moxifloxacin in prevention of post-cataract surgery endophthalmitis: a randomized controlled trial.Journal of cataract and refractive surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo study the efficacy of intracameral moxifloxacin 0.5% in prevention of postcataract surgery endophthalmitis. SETTINGS: 3 tertiary eye centers of northern India.
designMulticentric randomized clinical study.
methods60 000 eyes undergoing phacoemulsification with intraocular lens (IOL) implantation were randomized in 2 groups in 1:1 format from January 2018 to June 2024. Group 1 received intracameral moxifloxacin (cases), whereas group 2 did not receive intracameral antibiotics (control). Any case of endophthalmitis in the postoperative period up to 6 weeks in both groups was documented and managed according to routine protocols.
resultsThe endothelial cell counts were comparable preoperatively ( P = .18) and postoperatively ( P = .54). 6 eyes (0.02%) in the intracameral moxifloxacin group developed endophthalmitis as compared with 16 eyes in the control group (0.05%) ( P = .04). The odds of developing endophthalmitis were 2.5 times lower with the usage of intracameral moxifloxacin. The mean time of presentation of endophthalmitis in groups 1 and 2 was 32.26 ± 23.42 days and 23.52 ± 13.91 days, respectively. 8 cases (8/22; 36.36%) were culture-positive of which one was fungus (n = 1/8; 12.5%), while rest were bacteria (n = 7/8; 87.5%). Coagulase-negative Staphylococcus was the most commonly isolated microorganism (n = 4; 50%). Resistance to fluoroquinolones was higher for ciprofloxacin (5/7) and gatifloxacin (3/7) than moxifloxacin (2/7). At 3 months, 17 of 22 eyes (77.27%) responded to treatment and endophthalmitis resolved by 3 months. However, 1 eye in group 1 and 3 eyes in group 2 developed phthisis (4/22; 18.18%).
conclusionsIntracameral moxifloxacin is safe and effective in preventing postcataract surgery acute bacterial endophthalmitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.